The European Commission has authorised a €400 million German state aid package that prevents Sanofi from closing its insulin plant in Frankfurt-Höchst, a decision that keeps the European Economic Area from relying on a single production site for a medicine used daily by millions of diabetics.
The approval, announced on 10 September, ends a multi-year negotiation between Berlin, Paris and Brussels. Sanofi had made clear it would shut the German facility unless public funding bridged the gap to a new, highly automated production line. The company had also weighed moving the investment to France, according to German government sources cited in domestic media.
Why the case reached Brussels
Under the Services of General Economic Interest (SGEI) framework revised on 19 December 2025, member states can compensate companies for public service obligations in critical medicines without notifying the Commission, but only up to €20 million a year. Germany's package for Sanofi runs well above that ceiling, which triggered the full state aid assessment concluded this week.
The Commission's investigation focused on whether the aid was proportionate, whether it distorted competition, and whether the same outcome could have been achieved with less public money. In its decision, the executive concluded that the Frankfurt site closure would have created a structural dependency on non-European insulin supplies, a risk the EU has been trying to reduce since supply chain failures during the Covid-19 pandemic.
Conditions attached to the aid
Sanofi must have the new factory operational by 31 December 2032. From that date it is obliged to produce at least 1.1 tonnes of insulin a year and maintain a strategic stock of one tonne of active pharmaceutical ingredients. Both requirements remain in force until 2042. The company must also prioritise the European Economic Area market if shortages arise.
The Commission noted that insulin shortages have become more frequent as manufacturers divert production capacity toward GLP-1 receptor agonists, the class that includes Ozempic and Wegovy, which command higher margins. That commercial logic has left older, less profitable lines such as insulin under-invested.
The strategic context
A 2021 Commission study found that 80 per cent of the active pharmaceutical ingredients imported by the EU come from just five countries, with China alone supplying 45 per cent. That concentration was exposed as a liability when pandemic lockdowns disrupted global logistics. The Sanofi decision is the first major state aid case judged against that backdrop, and it arrives while the Critical Medicines Act, proposed in March 2025 and politically agreed by Council and Parliament on 11 May 2026, is still awaiting formal adoption.
Until the new legislation enters force, cases like this are assessed under existing state aid rules. The Commission issued separate guidance in March 2025 on how those rules should apply to critical medicines, signalling that further approvals of this kind are likely.
German and French manoeuvres
Berlin, the state of Hesse and the city of Frankfurt assembled the financial backing for Sanofi on the condition that the Commission signed off. French officials were simultaneously lobbying for the investment to land in France, where Sanofi has its headquarters and other production sites. The outcome keeps the jobs and the technology in Germany, but it also sets a precedent: large-scale aid for critical medicines can pass Brussels scrutiny if the strategic case is made convincingly.
What the numbers mean for patients
More than 32 million people in the EU live with diagnosed diabetes, and millions more are undiagnosed. For them, the Frankfurt decision is not about state aid law but about whether the vial they collect from the pharmacy each month continues to be filled in Europe. The Commission's own data shows that insulin shortages have risen in frequency over the past three years, a trend officials attribute directly to the GLP-1 capacity shift.
The 1.1 tonne annual production target is designed to cover a significant share of EEA demand, though the Commission has not published the exact percentage. Sanofi's existing Frankfurt site currently produces a fraction of that volume; the new line is intended to replace it entirely with modern, continuous manufacturing technology.
A test case for industrial policy
The decision illustrates how the Commission is using competition policy to advance strategic autonomy goals. By approving aid that exceeds the normal threshold, Brussels has signalled that security of supply for essential medicines can justify market intervention. The question now is whether the same logic will be applied to other critical generics, antibiotics, paracetamol, blood pressure drugs, where European production has also withered.
For Sanofi, the package secures a European footprint for a product line that is no longer a growth engine but remains a public health necessity. For the EU, it is a down payment on a resilience agenda that has so far produced more rhetoric than factories. The Frankfurt plant will be the first concrete test of whether that agenda can deliver.
People mentioned
Organisations
European Commission · Sanofi · German Federal Government
